SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $RHHBY–Genentech to present new data at ESMO across oncology portfolio including positive Phase III Krascendo 1 data in lung cancer

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.